Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of January 27

January 31st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 27, 2025.

Real-World UK, Ireland Study Confirms Long-Term Efficacy of SB5 in Psoriasis

January 30th 2025

By Skylar Jeremias

Article

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves Stelara Biosimilar

January 30th 2025

By Cameron Santoro

Article

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese regulatory agency approved a Stelara biosimilar.

Integrating Biosimilars Into Retina and Neurology Practices Requires Careful Planning

January 29th 2025

By Derek Burns, PharmD, MBA, BCPS, BCSCP

Article

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.

Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH

January 28th 2025

By Skylar Jeremias

Article

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a Russian study that expanded on a previous phase 3 study.

Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With Psoriasis

January 27th 2025

By Cameron Santoro

Article

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52.

Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets

January 26th 2025

By Skylar Jeremias

Article

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory announcements regarding new biosimilar products in Europe and Canada.

No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar

January 25th 2025

By Deana Ferreri, PhD

Article

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant differences in lab markers or disease activity between those on Remicade and those switched to biosimilar CT-P13 (Inflectra).

The Top 5 Biosimilar Articles for the Week of January 20

January 24th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 20, 2025.

Biosimilar Teriparatide Matches Forteo in Safety and Fracture Risk

January 23rd 2025

By Skylar Jeremias

Article

Biosimilar teriparatide has been shown to be as safe and effective as its reference product for osteoporosis treatment, potentially enabling significant cost savings in Japan’s health care system while addressing persistent misconceptions about biosimilar quality.